期刊
EMBO REPORTS
卷 23, 期 5, 页码 -出版社
WILEY
DOI: 10.15252/embr.202153820
关键词
antivirals; in vivo experiment; reverse genetics; SARS-CoV-2; serology
资金
- European Virus Archive Global (EVA GLOBAL) - European Union's Horizon 2020 research and innovation programme [871029]
- Fondation de France call FLASH COVID-19, project TAMAC
- Inserm through the REACTing (REsearch and ACTion targeting emerging infectious diseases) initiative
This study describes a simple method using infectious subgenomic amplicons (ISA) technology to generate recombinant infectious coronaviruses without the need for reconstruction of the complete genomic cDNA. This method has been successfully applied to SARS-CoV-2 and feline enteric coronavirus, enabling research on coronavirus reverse genetics, exploration of the molecular biological properties of SARS-CoV-2 variants, and acceleration of the development of effective therapeutic reagents.
Engineering recombinant viruses is a pre-eminent tool for deciphering the biology of emerging viral pathogens such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the large size of coronavirus genomes renders the current reverse genetics methods challenging. Here, we describe a simple method based on infectious subgenomic amplicons (ISA) technology to generate recombinant infectious coronaviruses with no need for reconstruction of the complete genomic cDNA and apply this method to SARS-CoV-2 and also to the feline enteric coronavirus. In both cases we rescue wild-type viruses with biological characteristics similar to original strains. Specific mutations and fluorescent red reporter genes can be readily incorporated into the SARS-CoV-2 genome enabling the generation of a genomic variants and fluorescent reporter strains for in vivo experiments, serological diagnosis, and antiviral assays. The swiftness and simplicity of the ISA method has the potential to facilitate the advance of coronavirus reverse genetics studies, to explore the molecular biological properties of the SARS-CoV-2 variants, and to accelerate the development of effective therapeutic reagents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据